Drug Trial Radar · NCT06781567
Clinical Trial of HG146 Administered to Participants With Adenoid Cystic Carcinoma
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
140
Planned (sponsor's estimate)
Start
Dec 13, 2024
Primary completion
Dec 31, 2028
Study completion Jun 30, 2029
Sponsor
- Lead sponsor
- HitGen Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II, open-label, non-randomized, multicenter study to evaluate the clinical efficacy and safety of HG146 in participants with recurrent or metastatic adenoid cystic carcinoma. This study is divided into two stages. 40 participants will be enrolled in the first stage. The efficacy and safty data will apply to make go or no go decision. Then the second stage will continue to enroll 100 Particapants.
Conditions
- Adenoid Cystic Carcinoma
- Head and Neck Cancer
Interventions
HG146Drug
HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- objective response rate (ORR)Time frame: From enrollment to the end of treatment at 4 weeks
- 6 Months Progression-Free Survival (PFS)Time frame: From enrollment to treatment at 6 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Oriental Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.